NO961113L - Behandling og forebyggelse av prostatakreft - Google Patents

Behandling og forebyggelse av prostatakreft

Info

Publication number
NO961113L
NO961113L NO961113A NO961113A NO961113L NO 961113 L NO961113 L NO 961113L NO 961113 A NO961113 A NO 961113A NO 961113 A NO961113 A NO 961113A NO 961113 L NO961113 L NO 961113L
Authority
NO
Norway
Prior art keywords
hydrogen
prostate cancer
ethyl
absent
halogen
Prior art date
Application number
NO961113A
Other languages
English (en)
Norwegian (no)
Other versions
NO961113D0 (no
Inventor
James Edmund Audia
Blake Lee Neubauer
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/407,822 external-priority patent/US5635197A/en
Priority claimed from US08/408,745 external-priority patent/US5629007A/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO961113D0 publication Critical patent/NO961113D0/no
Publication of NO961113L publication Critical patent/NO961113L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO961113A 1995-03-21 1996-03-19 Behandling og forebyggelse av prostatakreft NO961113L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/407,822 US5635197A (en) 1995-03-21 1995-03-21 Treatment and prevention of prostatic cancer metastasis
US08/408,745 US5629007A (en) 1995-03-21 1995-03-21 Method of preventing prostatic cancer development

Publications (2)

Publication Number Publication Date
NO961113D0 NO961113D0 (no) 1996-03-19
NO961113L true NO961113L (no) 1996-09-23

Family

ID=27020024

Family Applications (1)

Application Number Title Priority Date Filing Date
NO961113A NO961113L (no) 1995-03-21 1996-03-19 Behandling og forebyggelse av prostatakreft

Country Status (14)

Country Link
EP (1) EP0733365A3 (de)
JP (1) JPH08277220A (de)
KR (1) KR960034202A (de)
AU (1) AU695860B2 (de)
CA (1) CA2172211A1 (de)
CZ (1) CZ287977B6 (de)
HU (1) HUP9600702A3 (de)
IL (1) IL117537A (de)
MX (1) MX9601031A (de)
NO (1) NO961113L (de)
SG (1) SG47093A1 (de)
TW (1) TW450809B (de)
YU (1) YU16196A (de)
ZA (1) ZA962141B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5550134A (en) * 1995-05-10 1996-08-27 Eli Lilly And Company Methods for inhibiting bone loss
ZA979612B (en) * 1996-10-30 1999-04-28 Lilly Co Eli Synthesis of benzo(f)quinolinones
US6111110A (en) * 1996-10-30 2000-08-29 Eli Lilly And Company Synthesis of benzo[f]quinolinones
AU754604B2 (en) * 1998-07-29 2002-11-21 Merck & Co., Inc. Tricyclic compounds
US6436489B1 (en) 1999-03-24 2002-08-20 Clariant International Ltd. Fluorine-containing benzothiazoles, and their use in liquid-crystalline mixtures
GB0419850D0 (en) * 2004-09-07 2004-10-13 Angeletti P Ist Richerche Bio Therapeutic agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5239075A (en) * 1991-08-21 1993-08-24 Eli Lilly And Company Process for the preparation of benzo (f) quinolinones
ES2169026T3 (es) * 1991-08-21 2002-07-01 Lilly Co Eli Benzo(f)quinolinonas como inhibidores de 5-alfa-reductasa.

Also Published As

Publication number Publication date
AU695860B2 (en) 1998-08-27
SG47093A1 (en) 1998-03-20
HU9600702D0 (en) 1996-05-28
IL117537A0 (en) 1996-07-23
CA2172211A1 (en) 1996-09-22
IL117537A (en) 2001-01-11
MX9601031A (es) 1997-02-28
EP0733365A3 (de) 1997-03-05
KR960034202A (ko) 1996-10-22
YU16196A (sh) 1998-11-05
JPH08277220A (ja) 1996-10-22
AU4816896A (en) 1996-10-03
TW450809B (en) 2001-08-21
ZA962141B (en) 1997-09-15
CZ82596A3 (en) 1996-10-16
HUP9600702A3 (en) 1997-04-28
CZ287977B6 (cs) 2001-03-14
HUP9600702A2 (en) 1996-12-30
NO961113D0 (no) 1996-03-19
EP0733365A2 (de) 1996-09-25

Similar Documents

Publication Publication Date Title
TR199901653T2 (xx) Fitalazinonlar.
HUP0302955A2 (hu) HMG-CoA reduktáz inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk koleszterinnel kapcsolatos betegségek kezelésére
DE69433984D1 (de) Arylpiperazinderivate von indol als liganden der rezeptoren 5 ht1-like, 5 ht1b und 5 ht1d
MY138156A (en) Carbamate compounds for use in preventing or treating neurodegenerative disorders
MY157373A (en) Carbamate compounds for use in preventing or treating movement disorders
ATE319680T1 (de) Substituierte 2-benzylamino-2-phenyl- acetamidverbindungen
FR2699918B1 (fr) Ligands sélectifs des récepteurs 5HY1D-5HT1B dérivés d'indole-pipérazine utiles comme médicaments.
NO961113L (no) Behandling og forebyggelse av prostatakreft
DE69130326D1 (de) Piperidin-verbindungen, ihre darstellung und ihre verwendung
RS67603A (en) Carbamate compounds for use in the treatment of pain
DE60210976D1 (de) Carbamatverbindungen zur verwendung bei der prävention oder behandlung der bipolaren erkrankung
ZA982137B (en) Cycloalkylalkanecarboxamides and their preparation and use.
DE60210960D1 (de) Carbamat-verbindungen zur prävention oder behandlung von angstzuständen
HUP0002159A2 (hu) Eljárás peszticid hatóanyagok intermedierjeinek előállítására, az eljárásban alkalmazott új intermeierek és előállításuk
RS67503A (en) Carbamate compounds for use in preventing of treating psychotic disorders
TR200401511T4 (tr) Nöropatik ağrı ve baş ağrısı nöbetleri ve migren tipi baş ağrısı ile ilişkili ağrının önlenmesi veya tedavi edilmesinde kullanılan karbamat bileşikleri.
TR200001926T2 (tr) Vasküler başağrılarına karşı lokal anesteziklerin yeni kullanımı
BG104037A (en) 6-pyrrolidin-2-ylpyrindine derivatives, their preparation and application in therapy
ATE264840T1 (de) Azetidincarboxamid-derivate zur behandlung von zns störungen
NO20040176L (no) Karbamatforbindelser for anvendelse ved prevensjon eller terapi av neuropatisk smerte og kluster- og migrenehodepineassosiert smerte
HUP0300326A2 (hu) Vírusellenes hatású 4-oxo-1,4-dihidro-3-cinnolinkarboxamid-származékok, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
MY136347A (en) Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain
MY136733A (en) Carbamate compounds for use in preventing or treating psychotic disorders

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application